[Baseline analysis of refractory primary biliary cirrhosis]

Area of Science:

• Hepatology
• Gastroenterology
• Immunology

Context:

• Primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease.
• Ursodeoxycholic acid (UDCA) is a standard treatment for PBC.
• Refractory PBC indicates a suboptimal response to UDCA therapy.

Purpose:

• To compare clinical characteristics of refractory PBC versus typical PBC.
• To identify risk factors associated with poor prognosis in PBC patients treated with UDCA.

Summary:

• Sixty PBC patients receiving UDCA for over a year were classified as refractory (n=23) or typical (n=37) based on Paris criteria.
• Refractory PBC patients reported increased fatigue, pruritus, and jaundice.
• Elevated serum levels of ALT, AST, ALP, GGT, TBIL, DBIL, and IgM were observed in the refractory group compared to the typical group (P < 0.05).
• No significant differences were found in age, gender, autoantibody profiles, or liver biopsy findings between the groups.

Impact:

• Clinical features such as fatigue, pruritus, and jaundice, along with elevated biochemical markers, may predict a worse UDCA response.
• These findings can aid in identifying PBC patients at risk for rapid disease progression.
• This research contributes to personalized treatment strategies for PBC management.